Login to Your Account



Increlex First To FDA Finish Line In Gaining Short Stature Approval

By Aaron Lorenzo


Thursday, September 1, 2005
The FDA approved Tercica Inc.'s Increlex, a long-term treatment for growth failure in children with severe primary insulin-like growth factor-1 deficiency (IGFD), in a decision that has dealt a blow to a would-be competitor. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription